L Number	Hits	Search Text	DB	Time stamp
1	5	constitutive same androstane same receptor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/08/12 15:14

	U	1	Document ID	Issue Date	Pages	Title
1	☒	☐	US 20010055815 A1	20011227	13	Constitutive androstane receptor
2	☒	☐	US 20010034023 A1	20011025	210	Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
3	☒	☐	WO 200224918 A	20020328	39	New isolated human cytochrome P-450347 promoter region useful in screening for pharmacological agents comprises digital nuclear receptor binding motifs
4	☒	☐	US 20010055815 A	20011003	13	Screening a compound for its ability to inhibit binding of clotrimazole to a Constitutive Androstane Receptor ligand binding domain-containing polypeptide by competition binding
5	☐	☐	WO 200151045 A	20010719	75	Identifying agent for treating CAR-mediated disorder, involves screening agent that modulates CAR-mediated intermolecular interaction and determining if the agent modulates cholesterol level in test

	Current OR	Current XRef	Retrieval Classif	Inventor	S	C	P	2
1	436/518	435/7.5		Collins, Jon L. et al.	☐	☐	☐	☐
2	435/6	702/20		Stanton, Vincent P. JR. et al.	☐	☐	☐	☐
3				BERKENSTAM, A et al.	☐	☐	☐	☐
4				COLLINS, J L et al.	☐	☐	☐	☐
5				LEHMANN, J M et al.	☒	☐	☐	☐

	3	4	5	Image Doc. Displayed	PT
1	☐	☐	☐	US 20010055815	☐
2	☐	☐	☐	US 20010034023	☐
3	☐	☐	☐	WO 200224918 A1	☐
4	☐	☐	☐	US 20010055815	☐
5	☐	☐	☐	WO 200151045 A2	☐

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1649JXM

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 09	JAPIO to be reloaded August 18, 2002

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:18:17 ON 12 AUG 2002

=> file medline biosis embase caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION

FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 15:18:29 ON 12 AUG 2002

FILE 'BIOSIS' ENTERED AT 15:18:29 ON 12 AUG 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 15:18:29 ON 12 AUG 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:18:29 ON 12 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s constitutive (p) androstane (p) receptor

L1 219 CONSTITUTIVE (P) ANDROSTANE (P) RECEPTOR

=> s constitutive (p) androstane (p) receptor (p) screen?

L2 17 CONSTITUTIVE (P) ANDROSTANE (P) RECEPTOR (P) SCREEN?

=> s constitutive (p) androstane (p) receptor (p) screen? (p) compound

L3 4 CONSTITUTIVE (P) ANDROSTANE (P) RECEPTOR (P) SCREEN? (P) COMPOUN
D

=> s constitutive (p) androstane (p) receptor (p) assay (p) compound

L4 8 CONSTITUTIVE (P) ANDROSTANE (P) RECEPTOR (P) ASSAY (P) COMPOUND

=> s l2 and l3 and l4

L5 0 L2 AND L3 AND L4

=> s l2 or l3 or l4

L6 25 L2 OR L3 OR L4

=> dup rem l6

PROCESSING COMPLETED FOR L6
L7 10 DUP REM L6 (15 DUPLICATES REMOVED)

=> d l7 total ibib kwic

L7 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:240977 CAPLUS
DOCUMENT NUMBER: 136:274330
TITLE: Sequence of a human cytochrome P450 3A7 gene promoter region and uses in drug screening
INVENTOR(S): Berkenstam, Anders; Bertilsson, Goeran; Blomquist, Patrik
PATENT ASSIGNEE(S): Biovitrum AB, Swed.
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002024918 A1 20020328 WO 2001-SE2007 20010919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: SE 2000-3393 A 20000922
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The present invention relates to an isolated human cytochrome P 450 3A7 (CYP3A7) promoter region, and identifies the pregnane activated **receptor** (PAR) responsive element in the CYP3A7 promoter region. The invention further discloses that **constitutive androstane receptor** (CAR) can upregulate the CYP3A7 promoter via xenobiotic response element (XREM). The invention also relates to **screening** methods for agents modulating the expression of CYP3A7, such agents being potentially useful in modulating metab. of endogenous and/or exogenous **compds**., drug interaction, toxicity and/or bioavailability of drugs.

ST sequence human cytochrome P450 3A7 CYP3A7 promoter drug **screening** ; gene CYP3A7 promoter pregnane activated **receptor** responsive element PAR; promoter CYP3A7 **constitutive androstane receptor** CAR regulation

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CAR (**constitutive androstane receptor**);
sequence of a human cytochrome P 450 3A7 promoter region and uses in drug **screening**)

L7 ANSWER 2 OF 10 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 2002089312 MEDLINE
DOCUMENT NUMBER: 21659720 PubMed ID: 11706036
TITLE: Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.
AUTHOR: Kast Heidi R; Goodwin Bryan; Tarr Paul T; Jones Stacey A; Anisfeld Andrew M; Stoltz Catherine M; Tontonoz Peter; Kliewer Steve; Willson Timothy M; Edwards Peter A
CORPORATE SOURCE: Department of Biological Chemistry and Medicine, UCLA, Los Angeles, California 90095, USA.
CONTRACT NUMBER: HL30568 (NHLBI)
HL68445 (NHLBI)
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (2002 Jan 25) 277 (4) 2908-15.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200202
ENTRY DATE: Entered STN: 20020131
Last Updated on STN: 20020226
Entered Medline: 20020225

AB The multidrug resistance-associated protein 2 (MRP2, ABCC2), mediates the efflux of several conjugated **compounds** across the apical membrane of the hepatocyte into the bile canaliculi. We identified MRP2 in a **screen** designed to isolate genes that are regulated by the farnesoid X-activated **receptor** (FXR, NR1H4). MRP2 mRNA levels were induced following treatment of human or rat hepatocytes with either naturally occurring (chenodeoxycholic acid) or synthetic (GW4064) FXR

ligands. In addition, we have shown that MRP2 expression is regulated by the pregnane X **receptor** (PXR, NR1I2) and **constitutive androstane receptor** (CAR, NR1I3). Thus, treatment of rodent hepatocytes with PXR or CAR agonists results in a robust induction of MRP2 mRNA. . . 8 nucleotides (ER-8). PXR, CAR, and FXR bound with high affinity to this element as heterodimers with the retinoid X **receptor** alpha (RXRalpha, NR2B1). Luciferase reporter gene constructs containing 1 kb of the rat MRP2 promoter were prepared and transiently transfected. . . conferring PXR, CAR, and FXR responsiveness on a heterologous thymidine kinase promoter. Mutation of the ER-8 element abolished the nuclear **receptor** response. These studies demonstrate that MRP2 is regulated by three distinct nuclear **receptor** signaling pathways that converge on a common response element in the 5'-flanking region of this gene.

L7 ANSWER 3 OF 10 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 2002374737 MEDLINE
DOCUMENT NUMBER: 22116398 PubMed ID: 12120277
TITLE: PXR, CAR and drug metabolism.
AUTHOR: Willson Timothy M; Kliewer Steven A
CORPORATE SOURCE: GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, North Carolina 27709, USA.. tmw20653@gsk.com
SOURCE: Nat Rev Drug Discov, (2002 Apr) 1 (4) 259-66. Ref: 103
Journal code: 101124171.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200207
ENTRY DATE: Entered STN: 20020718
Last Updated on STN: 20020731
Entered Medline: 20020730

AB . . . harmful chemicals are also involved in drug metabolism, and can cause adverse drug-drug interactions. Two closely related orphan nuclear hormone **receptors**--the pregnane X **receptor** (PXR) and the **constitutive androstane receptor** (CAR)--have recently emerged as transcriptional regulators of cytochrome P450 expression that couple xenobiotic exposure to oxidative metabolism. In this review,. . . examination of the roles of PXR and CAR as xenobiotic sensors, and discuss the application of this knowledge to toxicological **screening** in drug discovery.

L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:713686 CAPLUS
DOCUMENT NUMBER: 135:267693
TITLE: **Constitutive androstane receptor** ligand **screening** using method involving clotrimazole
INVENTOR(S): Collins, Jon L.; Parks, Derek J.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001071361	A2	20010927	WO 2001-US9233	20010322
WO 2001071361	A3	20020606		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2001055815 A1 20011227 US 2001-814569 20010322
PRIORITY APPLN. INFO.: US 2000-191493P P 20000323

TI **Constitutive androstane receptor** ligand **screening** using method involving clotrimazole

ST **constitutive androstane receptor** ligand **screening** clotrimazole; human sequence **constitutive androstane receptor** LBD fragment

IT Androgen **receptors**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CAR (**constitutive androstane receptor**);
constitutive androstane receptor ligand **screening** using method involving clotrimazole)

IT Spheres
(beads, solid support; **constitutive androstane receptor** ligand **screening** using method involving clotrimazole and CAR ligand binding domain-contg. polypeptide attached to bead solid support)

IT Drug delivery systems
Drug **screening**
Protein sequences
(**constitutive androstane receptor** ligand **screening** using method involving clotrimazole)

IT Biotinylation
(**constitutive androstane receptor** ligand **screening** using method involving clotrimazole and CAR ligand binding domain-contg. polypeptide attached to coated bead solid support)

IT Fusion proteins (chimeric proteins)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**constitutive androstane receptor** ligand-binding domain; **constitutive androstane receptor** ligand **screening** using method involving clotrimazole)

IT Protein motifs
(ligand-binding domain of **constitutive androstane receptor**; **constitutive androstane receptor** ligand **screening** using method involving clotrimazole)

IT Avidins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(solid support bead coating; **constitutive androstane receptor** ligand **screening** using method involving clotrimazole and CAR ligand binding domain-contg. polypeptide attached to coated bead solid support)

IT 363631-04-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; **constitutive androstane receptor** ligand **screening** using method involving clotrimazole)

IT 23593-75-1, Clotrimazole 23593-75-1D, Clotrimazole, radiolabeled
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**constitutive androstane receptor** ligand **screening** using method involving clotrimazole)

IT 58-85-5, Biotin 9013-20-1, Streptavidin
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(solid support bead coating; **constitutive androstane receptor** ligand **screening** using method involving clotrimazole and CAR ligand binding domain-contg. polypeptide attached to coated bead solid support)

IT 363593-56-0 364059-93-8
RL: PRP (Properties)
(unclaimed sequence; **constitutive androstane receptor** ligand **screening** using method involving clotrimazole)

L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:525915 CAPLUS
DOCUMENT NUMBER: 135:127155
TITLE: **Screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia associated diseases
INVENTOR(S): Lehmann, Jurgen M.; Shiau, Andrew Kwan-Nan
PATENT ASSIGNEE(S): Tularik Inc., USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051045	A2	20010719	WO 2001-US1111	20010112
WO 2001051045	A3	20011220		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-176398P P 20000113

TI **Screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia associated diseases

ST **constitutive androstane receptor** CAR modulator **screening** hypercholesterolemia

IT Transcriptional regulation
(CAR-mediated; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CAR-responsive, DR-4 or DR-5; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Gene, animal
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(CAR.beta.; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Estrogen **receptors**
Glucocorticoid **receptors**
Mineralocorticoid **receptors**
Progesterone **receptors**
Retinoid **receptors**

Thyroid hormone **receptors**
Vitamin D **receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(DNA-binding domain from; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GAL4, DNA-binding domain from; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SRC-1 (steroid **receptor** coactivator-1), **receptor** binding domain of; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Antiarteriosclerotics
(antiatherosclerotics; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT mRNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(as a indicator for cholesterol level; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Lipids, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(blood; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Androgen **receptors**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**constitutive**, CAR.alpha. or CAR.beta.; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Mutation
(deletion, of CAR; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Resonance fluorescence
(energy transfer; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Fluorescent indicators
Isotope indicators
(for labeling CAR ligands; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Proteins, specific or class
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(green fluorescent, gene for, as reporter; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(high-d., as cholesterol indicator; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Mutation
(insertion, of CAR; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(labeled; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(low-d., as cholesterol indicator; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metabolic disorders, treatment of; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Fluorometry
(polarization; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Cardiovascular agents
Drug **screening**
Molecular cloning
(**screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Reporter gene
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sensor; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Mammal (Mammalia)
Mouse
(transgenic, CAE allele-disrupted; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Hypercholesterolemia
(treatment of; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(very-low-d., as cholesterol indicator; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 198705-46-3 301654-35-3 338961-03-8 351153-65-6 351153-66-7
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(CAR agonist; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 1153-51-1, 5.alpha.-androst-16-en-3.alpha.-ol 7657-50-3 95118-94-8, 5.alpha.-Androst-16-en-3.alpha.-ol acetate
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CAR ligand; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 225916-35-8
RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(amino acid sequence; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 9001-78-9, Alkaline phosphatase 9014-00-0, luciferase 9031-11-2, .beta.-Galactosidase 9040-07-7, Chloramphenicol acetyltransferase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(gene for, as reporter; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 81-88-9
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(labeled peptide; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 76150-91-9, 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene)
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(ligand for CAR; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 128-23-4, 5.beta.-pregnan-3,20 dione
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(ligand for CAR.alpha.; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 1404-04-2, neomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance gene as marker gene; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 57-88-5, cholesterol, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(serum; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 351237-24-6, 4: PN: WO0151045 SEQID: 4 unclaimed DNA 351237-25-7, 5: PN: WO0151045 SEQID: 5 unclaimed DNA 351237-26-8, 6: PN: WO0151045 SEQID: 6 unclaimed DNA 351237-27-9, 8: PN: WO0151045 SEQID: 8 unclaimed DNA 351237-29-1 351237-30-4
RL: PRP (Properties)
(unclaimed nucleotide sequence; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

IT 197731-92-3 351237-22-4 351237-23-5 351237-28-0
RL: PRP (Properties)
(unclaimed protein sequence; **screening constitutive androstane receptor** (CAR) modulators for treatment of hypercholesterolemia assocd. diseases)

L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:168249 CAPLUS
DOCUMENT NUMBER: 134:217982
TITLE: Chromatin-based RAR/RXR heterodimer-regulated transcription system and its use in screening for transcription modulators
INVENTOR(S): Chambon, Pierre; Dilworth, F. Jeffrey; Fromental-Ramain, Catherine

PATENT ASSIGNEE(S): Institut National de la Sante et de la Recherche Medicale, Fr.; Centre National de la Recherche Scientifique; Universite Louis Pasteur; Bristol-Myers Squibb Company
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016597	A1	20010308	WO 1999-US20018	19990901

W: AU, CA, IL, JP, MX, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT **Receptors**
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(CAR (**constitutive androstane receptors**);
chromatin-based RAR/RXR heterodimer-regulated transcription system and its use in **screening** for transcription modulators)

L7 ANSWER 7 OF 10 MEDLINE DUPLICATE 3
ACCESSION NUMBER: 2001475469 MEDLINE
DOCUMENT NUMBER: 21410114 PubMed ID: 11518807
TITLE: Conservation of signaling pathways of xenobiotic-sensing orphan nuclear receptors, chicken xenobiotic receptor, constitutive androstane receptor, and pregnane X receptor, from birds to humans.
AUTHOR: Handschin C; Podvinec M; Stockli J; Hoffmann K; Meyer U A
CORPORATE SOURCE: Division of Pharmacology/Neurobiology, Biozentrum of the University of Basel, CH-4056 Basel, Switzerland.
SOURCE: MOLECULAR ENDOCRINOLOGY, (2001 Sep) 15 (9) 1571-85.
Journal code: 8801431. ISSN: 0888-8809.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200201
ENTRY DATE: Entered STN: 20010827
Last Updated on STN: 20020125
Entered Medline: 20020114

AB Chicken xenobiotic **receptor**, pregnane X **receptor**, and **constitutive androstane receptor** are orphan nuclear **receptors** that have recently been discovered to regulate drug- and steroid-mediated induction of hepatic cytochromes P450 (CYP). This induction is part. . . experiments in the chicken hepatoma cell line LMH that suggest evolutionary conservation of the signaling pathways triggered by pregnane X **receptor**, **constitutive androstane receptor**, and chicken xenobiotic **receptor**. Thus, the phenobarbital-inducible enhancer units of the mouse Cyp2b10, rat CYP2B2, and human CYP2B6 genes were activated in reporter gene **assays** by the same **compounds** that activate the chicken CYP2H1 phenobarbital-inducible enhancer units. Chicken xenobiotic **receptor**, pregnane X **receptor**, and **constitutive androstane receptor** all bound to the CYP2H1 phenobarbital-inducible enhancer units in gel-shift experiments. In CV-1 cell transactivation **assays**, mammalian pregnane X **receptors** activate the chicken phenobarbital-inducible enhancer units to the same extent as does chicken xenobiotic **receptor**, each **receptor** maintaining its species-specific ligand spectrum. To assess the reported role of protein phosphorylation in

drug-mediated induction, we treated LMH cells. . . comparable to those seen on CYP2Bs and CYP3As in mammalian primary hepatocyte cultures. These results indicate that closely related nuclear **receptors**, transcription factors, and signaling pathways are mediating the transcriptional activation of multiple genes by xenobiotics in chicken, rodents, and man.

L7 ANSWER 8 OF 10 MEDLINE DUPLICATE 4
ACCESSION NUMBER: 2000270219 MEDLINE
DOCUMENT NUMBER: 20270219 PubMed ID: 10748001
TITLE: Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands.
AUTHOR: Moore L B; Parks D J; Jones S A; Bledsoe R K; Consler T G; Stimmel J B; Goodwin B; Liddle C; Blanchard S G; Willson T M; Collins J L; Kliewer S A
CORPORATE SOURCE: Department of Molecular Endocrinology, Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709, USA.
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (2000 May 19) 275 (20) 15122-7.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200006
ENTRY DATE: Entered STN: 20000629
Last Updated on STN: 20000629
Entered Medline: 20000621

AB Xenobiotics induce the transcription of cytochromes P450 (CYPs) 2B and 3A through the **constitutive androstane receptor** (CAR; NR1I3) and pregnane X **receptor** (PXR; NR1I2), respectively. In this report, we have systematically compared a series of xenobiotics and natural steroids for their effects. . . on mouse and human CAR and PXR. Our results demonstrate dual regulation of PXR and CAR by a subset of **compounds** that affect CYP expression. Moreover, there are marked pharmacological differences between the mouse (m) and human (h) orthologs of both. . . PXR. Similarly, the PXR activator clotrimazole is a potent deactivator of hCAR. Using radioligand binding and fluorescence resonance energy transfer **assays**, we demonstrate that several of the **compounds** that regulate mouse and human CAR, including natural steroids, bind directly to the **receptors**. Our results suggest that CAR, like PXR, is a steroid **receptor** that is capable of recognizing structurally diverse **compounds**. Moreover, our findings underscore the complexity in the physiologic response to xenobiotics.

L7 ANSWER 9 OF 10 MEDLINE DUPLICATE 5
ACCESSION NUMBER: 2001305626 MEDLINE
DOCUMENT NUMBER: 20525078 PubMed ID: 11075820
TITLE: Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene.
AUTHOR: Kawamoto T; Kakizaki S; Yoshinari K; Negishi M
CORPORATE SOURCE: Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
SOURCE: MOLECULAR ENDOCRINOLOGY, (2000 Nov) 14 (11) 1897-905.
Journal code: 8801431. ISSN: 0888-8809.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals

ENTRY MONTH: 200105
ENTRY DATE: Entered STN: 20010604
Last Updated on STN: 20010604
Entered Medline: 20010531

AB The nuclear orphan **receptor** CAR (constitutively active **receptor** or **constitutive androstane receptor**) can be activated in response to xenochemical exposure, such as activation by phenobarbital of a response element called NR1 found in the CYP2B gene. Here various steroids were **screened** for potential endogenous chemicals that may activate CAR, using the NR1 enhancer and Cyp2b10 induction in transfected HepG2 cell and/or. . . is an effective activator of CAR in both female and male mice, suggesting a biological and/or toxicological role of this **receptor** in estrogen metabolism. In addition to mouse CAR, estrogens activated rat CAR, whereas human CAR did not respond well to. . .

L7 ANSWER 10 OF 10 MEDLINE DUPLICATE 6
ACCESSION NUMBER: 1998322543 MEDLINE
DOCUMENT NUMBER: 98322543 PubMed ID: 9658407
TITLE: Molecular cloning of xSRC-3, a novel transcription coactivator from Xenopus, that is related to AIB1, p/CIP, and TIF2.
AUTHOR: Kim H J; Lee S K; Na S Y; Choi H S; Lee J W
CORPORATE SOURCE: College of Pharmacy, Chonnam National University, Kwangju, South Korea.
SOURCE: MOLECULAR ENDOCRINOLOGY, (1998 Jul) 12 (7) 1038-47.
Journal code: 8801431. ISSN: 0888-8809.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199810
ENTRY DATE: Entered STN: 19981020
Last Updated on STN: 19981020
Entered Medline: 19981005

AB Nuclear **receptors** regulate transcription by binding to specific DNA response elements of target genes. Herein, we report the molecular cloning and characterization of a novel Xenopus cDNA encoding a transcription coactivator xSRC-3 by using retinoid X **receptor** (RXR) as a bait in the yeast two-hybrid **screening**. It belongs to a growing coactivator family that includes a steroid **receptor** coactivator amplified in breast cancer (AIB1), p300/ CREB-binding protein (CBP)-interacting protein (p/ CIP), and transcriptional intermediate factor 2 (TIF2). It also interacts with a series of nuclear **receptors** including retinoic acid **receptor** (RAR), thyroid hormone **receptor** (TR), and orphan nuclear **receptors** [hepatocyte nuclear **receptor** 4 (HNF4) and **constitutive androstane receptor** (CAR)]. However, it does not interact with small heterodimer partner (SHP), an orphan nuclear **receptor** known to antagonize ligand-dependent transactivation of other nuclear **receptors**. In CV-1 cells, cotransfection of xSRC-3 differentially stimulates ligand-induced transactivation of RXR, TR, and RAR in a dose-dependent manner. Interestingly,. . . and early stages of oocyte development, suggesting that studies of xSRC-3 may lead to better understanding of the roles nuclear **receptors** play in oocyte development as well as liver-specific gene expression.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	38.98	39.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.62	-0.62

STN INTERNATIONAL LOGOFF AT 15:21:43 ON 12 AUG 2002

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1649JXM

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 09	JAPIO to be reloaded August 18, 2002

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

1: Mol Pharmacol 2002 Jan;61(1):1-6 Related Articles, Links

Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital.

Ueda A, Hamadeh HK, Webb HK, Yamamoto Y, Sueyoshi T, Afshari CA, Lehmann JM, Negishi M.

Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.

Phenobarbital (PB) induces various gene encoding drug/steroid-metabolizing enzymes such as cytochromes P450 (P450s) and transferases. Although the nuclear orphan constitutive active receptor (CAR) has been identified as a key transcription factor that regulates the induction of CYP2B, the full scope of CAR-regulated genes still remains a major question. To this end, reverse transcriptase-polymerase chain reaction and cDNA microarray techniques were employed to examine gene expression in wild-type and CAR-null mice. The results show that a total of 138 genes were detected to be either induced or repressed in response to PB treatment, of which about half were under CAR regulation. Including CYP2B10, CYP3A11, and NADPH-CYP reductase, CAR regulated a group of the PB-induced drug/steroid-metabolizing enzymes. Enzymes such as amino levulinate synthase 1 and squalene epoxidase displayed CAR-independent induction by PB. Cyp4a10 and Cyp4a14 represented the group of genes induced by PB only in CAR-null mice, indicating that CAR may be a transcription blocker that prevents these genes from being induced by PB. Additionally, the group of genes encoding enzymes and proteins involved in basic biological processes such as energy metabolism underwent the CAR-dependent repression by PB. Thus, CAR seems to have diverse roles, both as a positive and negative regulator, in the regulation of hepatic genes in response to PB beyond drug/steroid metabolism.

PMID: 11752199 [PubMed - indexed for MEDLINE]

1: Mol Cell Biol 1994 Mar;14(3):1544-51

Related Articles, Nucleotide, OMIM, Protein, Books, LinkOut

A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements.

Baes M, Gulick T, Choi HS, Martinoli MG, Simha D, Moore DD.

Department of Molecular Biology, Massachusetts General Hospital, Boston 02114.

We have identified and characterized a new orphan member of the nuclear hormone receptor superfamily, called MB67, which is predominantly expressed in liver. MB67 binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes, both of which consist of a direct repeat hexamers related to the consensus AGGTCA, separated by 5 bp. MB67 binds these elements as a heterodimer with the 9-cis-retinoic acid receptor, RXR. However, MB67 does not bind or activate other retinoic acid response elements with alternative hexamer arrangements or any of several other wild-type and synthetic hormone response elements examined. The transactivation of retinoic acid response elements by MB67 is weaker than that conferred by the retinoic acid receptors but does not require the presence of all-trans retinoic acid, 9-cis-retinoic acid, or any exogenously added ligand. We propose that MB67 plays an important role in the complex network of proteins that govern response to retinoic acid and its metabolites.

MeSH Terms:

- Amino Acid Sequence
- Base Sequence
- Cloning, Molecular
- DNA Primers/chemistry
- DNA, Complementary/genetics
- DNA-Binding Proteins/genetics*
- Gene Expression Regulation*
- Human
- Molecular Sequence Data
- Receptors, Cytoplasmic and Nuclear/genetics*

1: Z30425. H.sapiens mRNA fo...[gi:458541]

ProbeSet, MapView, Related Sequences, OMIM, Protein, PubMed, SNP, Taxonomy, UniSTS, LinkOut

```
LOCUS       HSONHORE                1450 bp    mRNA    linear   PRI 07-MAR-1995
DEFINITION  H.sapiens mRNA for orphan nuclear hormone receptor.
ACCESSION   Z30425 L29263
VERSION     Z30425.1  GI:458541
KEYWORDS    nuclear hormone receptor; orphan receptor.
SOURCE      Homo sapiens.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1450)
  AUTHORS   Baes,M., Gulick,T., Choi,H.S., Martinoli,M.G., Simha,D. and
            Moore,D.D.
  TITLE     A new orphan member of the nuclear hormone receptor superfamily
            that interacts with a subset of retinoic acid response elements
  JOURNAL   Mol. Cell. Biol. 14 (3), 1544-1551 (1994)
  MEDLINE   94158827
   PUBMED   8114692
REFERENCE   2  (bases 1 to 1450)
  AUTHORS   Moore,D.D.
  TITLE     Direct Submission
  JOURNAL   Submitted (04-MAR-1994) David D. Moore, Molecular Biology,
            Massachusetts General Hospital, Boston, MA, 02114, USA
FEATURES             Location/Qualifiers
     source          1..1450
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="mb67"
                     /tissue_type="liver"
                     /clone_lib="cDNA"
     CDS             273..1319
                     /codon_start=1
                     /product="orphan nuclear hormone receptor"
                     /protein_id="CAA83016.1"
                     /db_xref="GI:458542"
                     /db_xref="SPTREMBL:Q14994"
                     /translation="MASREDELRNCVVCGDQATGYHFNALTCEGCKGFFRRTVSKSIG
                     PTCPFAGSCEVSKTQRRHCPACRLQKCLDAGMRKDMILSAEALALRRAKQAQRRAQQT
                     PVQLSKEQEELIRTLLGAHTRHMGTMFEQFVQFRPPAHLFIHHQPLPTLAPVLPLVTH
                     FADINTFMVLQVIKFTKDLPVFRSLPIEDQISLLKGAAVEICHIVLNTTFCLQTQNFL
                     CGPLRYTIEDGARVGFQVEFLELLFHFHGTLRKLQLQEPEYVLLAAMALFSPDRPGVT
                     QRDEIDQLQEEMALTLQSYIKGQQRRPRDRFLYAKLLGLLAELRSINEAYGYQIQHIQ
                     GLSAMMPLLQEICS"
BASE COUNT      359 a    399 c    380 g    312 t
ORIGIN
        1 gtgagcttgc tccttaagtt acaggaactc tccttataat agacacttca ttttcctagt
       61 ccatccctca tgaaaaatga ctgaccactg ctgggcagca ggagggatga taatcctaac
      121 tccaatcact ggcaactcct gagatcagag gaaaaccagc aacagcgtgg gagtttgggg
      181 agaggcattc cataccagat tctgtggcct gcaggtgaca tgctgcctaa gagaagcagg
      241 agtctgtgac agccacccca acacgtgacg tcatggccag tagggaagat gagctgagga
      301 actgtgtggt atgtggggac caagccacag gctaccactt taatgcgctg acttgtgagg
```

```
      361 gctgcaaggg tttcttcagg agaacagtca gcaaaagcat tggtcccacc tgccccttg
      421 ctggaagctg tgaagtcagc aagactcaga ggcgccactg cccagcctgc aggttgcaga
      481 agtgcttaga tgctggcatg aggaaagaca tgatactgtc ggcagaagcc ctggcattgc
      541 ggcgagcaaa gcaggcccag cggcgggcac agcaaacacc tgtgcaactg agtaaggagc
      601 aagaagagct gatccggaca ctcctggggg cccacacccg ccacatgggc accatgtttg
      661 aacagtttgt gcagtttagg cctccagctc atctgttcat ccatcaccag cccttgccca
      721 ccctggcccc tgtgctgcct ctggtcacac acttcgcaga catcaacact ttcatggtac
      781 tgcaagtcat caagtttact aaggacctgc ccgtcttccg ttccctgccc attgaagacc
      841 agatctccct tctcaaggga gcagctgtgg aaatctgtca catcgtactc aataccactt
      901 tctgtctcca aacacaaaac ttcctctgcg ggcctcttcg ctacacaatt gaagatggag
      961 cccgtgtggg gttccaggta gagtttttgg agttgctctt tcacttccat ggaacactac
     1021 gaaaactgca gctccaagag cctgagtatg tgctcttggc tgccatggcc ctcttctctc
     1081 ctgaccgacc tggagttacc cagagagatg agattgatca gctgcaagag gagatggcac
     1141 tgactctgca aagctacatc aagggccagc agcgaaggcc ccgggatcgg tttctgtatg
     1201 cgaagttgct aggcctgctg gctgagctcc ggagcattaa tgaggcctac gggtaccaaa
     1261 tccagcacat ccagggcctg tctgccatga tgccgctgct ccaggagatc tgcagctgag
     1321 gccatgctca cttccttccc cagctcacct ggaacaccct ggatacactg gagtgggaaa
     1381 atgctgggac caaagattgg gccgggttca aagggagccc agtggttgca atgaaagact
     1441 aaagcaaaac
//
```

Revised: July 5, 2002.

CAR : 102

```
RESULT   5
W37798
ID   W37798 standard; protein; 202 AA.
XX
AC   W37798;
XX
DT   28-JUL-1998  (first entry)
XX
DE   Amino acid sequence of cancer-associated retinopathy (CAR)
antigen.
XX
KW   Cancer-associated retinopathy; CAR; antigen; antibody;
KW   immunoassay reagent; detection of CAR antibody; cancer.
XX
OS   Homo sapiens.
XX
PN   US5753522-A.
XX
PD   19-MAY-1998.
XX
PF   10-APR-1995;   95US-0419102.
XX
PR   10-APR-1995;   95US-0419102.
PR   06-DEC-1991;   91US-0804894.
XX
PA   (LEGA-) LEGACY GOOD SAMARITAN HOSPITAL & MEDICAL.
XX
PI   Palczewski K,  Polans AS;
XX
DR   WPI; 1998-311413/27.
XX
PT   Cancer-associated retinopathy antigen proteins - are useful in
PT   immunoassays for detection of cancer-associated retinopathy
PT   antibodies for early diagnosis of cancer
XX
PS   Claim 1; Fig 2; 11pp; English.
XX
CC   This amino acid sequence is of the cancer-associated retinopathy
CC   (CAR) antigen, which are specifically bound by CAR antibodies.
CC   The antigen and any peptides resulting from it are used as
CC   immunoassay reagents for detecting CAR antibodies, e.g. as an
CC   early warning of cancer.
XX
SQ   Sequence   202 AA;


  Query Match             24.8%;  Score 332.5;  DB 19;  Length 202;
  Best Local Similarity   36.3%;  Pred. No. 5.3e-27;
  Matches   65;  Conservative   45;  Mismatches   66;  Indels    3;
Gaps    2;

Qy      77 EGLDQLQAQTKFTKKELQSLYRGFKNECPTGLVDEDTFKLIYAQFFPQGDATTYAHFLFN
136
           | |::||  ||||::|| | |: | |||:| :    |: ||::|||: |   ||  :|
Db      12 eileelqlntkfteeelsswyqsflkecpsgritrqefqtiyskffpeadpkayaqhvfr
71
```

```
Qy      137 AFDADGNGAIHFEDFVVGLSILLRGTVHEKLKWAFNLYDINKDGYITKEEMLAIMKSIYD
196

            :|||: :| : |:::|: | :   |  ::||:|||:|||:: :| |:| |:| |: :|:
Db       72 sfdansdgtldfkeyvialhmtsagktnqklewafslydvdgngtisknevleivtaifk
131

Qy      197 MMGRHTYPILRED--APAEHVERFFEKMDRNQDGVVTIEEFLEACQKDENIMSSMQLFE
253

            |:       | ||   | :  |: :    :  |  :| :||:|    :: |:  :| ||
Db      132 mispedtkhlpedentpekraekiwgffgkkdddkltekefiegtlankeilrliq-fe
189
```